Significance of Laboratory Examination in The Diagnosis of Ulcerative Colitis_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 KUAIGuo-hu ¹ ,  LIChun-yu ²

1. Department of Neurosurgery, Tianyou Hospital, Wuhan University of Science and Technology, Wuhan 430064, Hubei Province, China;
2. Department of Colorectal Surgery, The Forth Hospital, China Medical University, Shenyang 110032, Liaoning Province, China;

Corresponding author：

LIChun-yu, Email: lcy133000@163.com

Keywords：

Ulcerative colitis; Diagnosis; Non-invasive examination; Laboratory examination

DOI：

10.7507/1007-9424.20140093

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the significance of laboratory examinations in diagnosis of ulcerative colitis (UC). Methods Literatures at home and abroad were searched to review the clinical significance of laboratory examinations indexes in diagnosis of UC. Results Anti-neutrophilcytoplasmicantibodies (ANCA) had some value in diagnosis of UC, but it was limited in evaluation of UC in active patients. The positive rate of anti-intestinal goblet cell antibody (GAB) in patients with UC was higher than that of patients with Crohn's disease (CD), so it could be used as identification indexes of the two diseases, but it could not reflect the severity of the disease. Anti-saccharomyces cerevisiae antibodies (ASCA) and anti-pancreatic antibody (PAB) were mainly used in the differential diagnosis of UC and CD, but they had no significant advantages in diagnosis of UC. Fecal calprotectin (FCP) played a positive role in evaluation of recurrence and activity in UC. Although lactoferrin, M2-pyruvate kinase (M2-PK), and S100A12 were not as effective as FCP, but if combined with related indicators, they were also important. Conclusions Of the relevant indexes of laboratory examination in the diagnosis of UC, FCP plays an importent role in the evaluation of recurrence and activity of UC.

Citation： KUAIGuo-hu, LIChun-yu. Significance of Laboratory Examination in The Diagnosis of Ulcerative Colitis. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2014, 21(3): 383-387. doi: 10.7507/1007-9424.20140093 Copy

1.	李艳萍. 867例抗中性粒细胞胞浆抗体检测的临床分析[J].吉林医学, 2012, 33(11):2265-2266.
2.	吴登峰, 王承党.福建省溃疡性结肠炎住院患者病情回顾分析[J].胃肠病学和肝病学杂志, 2010, 19(7):639-642.
3.	邱丽.检测核周型抗中性粒细胞胞浆抗体在溃疡性结肠炎中的意义[J].浙江临床医学, 2012, 14(12):1471-1472.
4.	王琼, 杨晓钟, 马刚.自身抗体及相关抗原检测对炎症性肠病患者的临床意义研究[J].齐齐哈尔医学院学报, 2010, 31(23):3709-3711.
5.	邱洁英, 刘光金, 杨小金.实验室检测对溃疡性结肠炎患者诊断和评估预后的相关研究[J].实验与检验医学, 2010, 28(2):153-154, 158.
6.	Lawrance IC, Murray K, Hall A, et al. A prospective comparative study of ASCA and pANCA in Chinese and Caucasian IBD patients[J]. Am J Gastroenterol, 2004, 99(11):2186-2194.
7.	Oudkerk Pool M, Bouma G, Meuwissen SG, et al. Serological markers to differentiate between ulcerative colitis and Crohn's disease[J]. J Clin Pathol, 1995, 48(4):346-350.
8.	范如英, 武子涛, 盛剑秋.核周型抗中性粒细胞胞浆抗体在溃疡性结肠炎诊断中的意义[J].胃肠病学和肝病学杂志, 2012, 21(8):758-759.
9.	杨冬, 王贞.炎症性肠病血清相关抗体检测的临床价值[J].大连医科大学学报, 2010, 32(3):343-347.
10.	何淳, 张蜀澜, 李永哲, 等.炎症性肠病患者中四种自身抗体联合检测的临床意义[J].标记免疫分析与临床, 2008, 15(5):268-271.
11.	Lawrance IC, Hall A, Leong R, et al. A comparative study of goblet cell and pancreatic exocine autoantibodies combined with ASCA and pANCA in Chinese and Caucasian patients with IBD[J]. Inflamm Bowel Dis, 2005, 11(10):890-897.
12.	Kuna AT. Serological markers of inflammatory bowel disease[J]. Biochem Med (Zagreb), 2013, 23(1):28-42.
13.	Kovacs M, Lakatos PL, Papp M, et al. Pancreatic autoantibodies and autoantibodies against goblet cells in pediatric patients with inflammatory bowel disease[J]. J Pediatr Gastroenterol Nutr, 2012, 55(4):429-435.
14.	王志红, 赵晓军, 韩英.抗中性粒细胞胞质抗体和抗酿酒酵母抗体表达在炎症性肠病诊断中的意义[J].解放军医学杂志, 2008, 33(10):1244-1245.
15.	Saibeni S, Folli C, de Franchis R, et al. Diagnostic role and clinical correlates of anti-saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases[J]. Dig Liver Dis, 2003, 35(12):862-868.
16.	Kiliç ZM, Tunç B, Ayaz S, et al. Antineutrophil cytoplasmic autoantibodies and anti-saccharomyces cerevisiae antibodies in inflammatory bowel diseases[J]. Turk J Gastroenterol, 2004, 15(4):238-242.
17.	Demirsoy H, Ozdil K, Ersoy O, et al. Anti-pancreatic antibody in Turkish patients with inflammatory bowel disease and first-degree relatives[J]. World J Gastroenterol, 2010, 16(45):5732-5738.
18.	Homsak E, Micetić-Turk D, Bozic B. Autoantibodies pANCA, GAB and PAB in inflammatory bowel disease:prevalence, charac-teristics and diagnostic value[J]. Wien Klin Wochenschr, 2010, 122 Suppl 2:19-25.
19.	Fagerhol MK, Dale I, Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells[J]. Bull Eur Physiopathol Respir, 1980, 16 Suppl:273-282.
20.	Rugtveit J, Brandtzaeg P, Halstensen TS, et al. Increased macro-phage subset in inflammatory bowel disease:apparent recruitment from peripheral blood monocytes[J]. Gut, 1994, 35(5):669-674.
21.	Røseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein[J]. Digestion, 1997, 58(2):176-180.
22.	Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease[J]. Dig Liver Dis, 2009, 41(1):56-66.
23.	沈姞, 李俊霞, 王化虹, 等.粪便钙卫蛋白对溃疡性结肠炎的诊断及预测复发的价值[J].肠外与肠内营养, 2011, 18(5):272-276.
24.	Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes[J]. Inflamm Bowel Dis, 2013, 19(2):332-341.
25.	Lobatón T, Rodríguez-Moranta F, Lopez A, et al. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis[J]. Inflamm Bowel Dis, 2013, 19(5):1034-1042.
26.	Mao R, Xiao YL, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases:a meta-analysis of pros-pective studies[J]. Inflamm Bowel Dis, 2012, 18(10):1894-1899.
27.	张颖, 王英德.粪便钙卫蛋白、抗中性粒细胞胞浆抗体检测在溃疡性结肠炎诊断中的价值比较[J].中华临床医师杂志:电子版, 2012, 6(6):1620-1622.
28.	王少东, 施惠, 陆恒, 等.粪便钙卫蛋白在全消化系统疾病鉴别诊断中的意义[J].胃肠病学, 2012, 17(4):237-239.
29.	Vieira A, Fang CB, Rolim EG, et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin:correlation with laboratory parameters, clinical, endoscopic and histological indexes[J]. BMC Res Notes, 2009, 2:221.
30.	Gisbert JP, Bermejo F, Pérez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse[J]. Inflamm Bowel Dis, 2009, 15(8):1190-1198.
31.	向军英, 欧阳钦, 李国栋.粪便乳铁蛋白在评价溃疡性结肠炎活动性中的价值[J].中华医学杂志, 2007, 87(32):2262-2264.
32.	Fahlgren A, Hammarström S, Danielsson A, et al. Increased expression of antimicrobial peptides and lysozyme in colonic epithelial cells of patients with ulcerative colitis[J]. Clin Exp Immunol, 2003, 131(1):90-101.
33.	Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis:a prospective multicentre comparison of predicting outcomes and monitoring response[J]. Gut, 2010, 59(9):1207-1212.
34.	Johnson MW, Maestranzi S, Duffy AM, et al. Faecal M2-pyruvate kinase:a novel, noninvasive marker of ileal pouch inflammation[J]. Eur J Gastroenterol Hepatol, 2009, 21(5):544-550.
35.	Chung-Faye G, Hayee B, Maestranzi S, et al. Fecal M2-pyruvate kinase (M2-PK):a novel marker of intestinal inflammation[J]. Inflamm Bowel Dis, 2007, 13(11):1374-1378.
36.	Däbritz J, Langhorst J, Lügering A, et al. Improving relapse prediction in inflammatory bowel disease by neutrophil-derived S100A12[J]. Inflamm Bowel Dis, 2013, 19(6):1130-1138.
37.	Kaiser T, Langhorst J, Wittkowski H, et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome[J]. Gut, 2007, 56(12):1706-1713.

1. 李艳萍. 867例抗中性粒细胞胞浆抗体检测的临床分析[J].吉林医学, 2012, 33(11):2265-2266.
2. 吴登峰, 王承党.福建省溃疡性结肠炎住院患者病情回顾分析[J].胃肠病学和肝病学杂志, 2010, 19(7):639-642.
3. 邱丽.检测核周型抗中性粒细胞胞浆抗体在溃疡性结肠炎中的意义[J].浙江临床医学, 2012, 14(12):1471-1472.
4. 王琼, 杨晓钟, 马刚.自身抗体及相关抗原检测对炎症性肠病患者的临床意义研究[J].齐齐哈尔医学院学报, 2010, 31(23):3709-3711.
5. 邱洁英, 刘光金, 杨小金.实验室检测对溃疡性结肠炎患者诊断和评估预后的相关研究[J].实验与检验医学, 2010, 28(2):153-154, 158.
6. Lawrance IC, Murray K, Hall A, et al. A prospective comparative study of ASCA and pANCA in Chinese and Caucasian IBD patients[J]. Am J Gastroenterol, 2004, 99(11):2186-2194.
7. Oudkerk Pool M, Bouma G, Meuwissen SG, et al. Serological markers to differentiate between ulcerative colitis and Crohn's disease[J]. J Clin Pathol, 1995, 48(4):346-350.
8. 范如英, 武子涛, 盛剑秋.核周型抗中性粒细胞胞浆抗体在溃疡性结肠炎诊断中的意义[J].胃肠病学和肝病学杂志, 2012, 21(8):758-759.
9. 杨冬, 王贞.炎症性肠病血清相关抗体检测的临床价值[J].大连医科大学学报, 2010, 32(3):343-347.
10. 何淳, 张蜀澜, 李永哲, 等.炎症性肠病患者中四种自身抗体联合检测的临床意义[J].标记免疫分析与临床, 2008, 15(5):268-271.
11. Lawrance IC, Hall A, Leong R, et al. A comparative study of goblet cell and pancreatic exocine autoantibodies combined with ASCA and pANCA in Chinese and Caucasian patients with IBD[J]. Inflamm Bowel Dis, 2005, 11(10):890-897.
12. Kuna AT. Serological markers of inflammatory bowel disease[J]. Biochem Med (Zagreb), 2013, 23(1):28-42.
13. Kovacs M, Lakatos PL, Papp M, et al. Pancreatic autoantibodies and autoantibodies against goblet cells in pediatric patients with inflammatory bowel disease[J]. J Pediatr Gastroenterol Nutr, 2012, 55(4):429-435.
14. 王志红, 赵晓军, 韩英.抗中性粒细胞胞质抗体和抗酿酒酵母抗体表达在炎症性肠病诊断中的意义[J].解放军医学杂志, 2008, 33(10):1244-1245.
15. Saibeni S, Folli C, de Franchis R, et al. Diagnostic role and clinical correlates of anti-saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases[J]. Dig Liver Dis, 2003, 35(12):862-868.
16. Kiliç ZM, Tunç B, Ayaz S, et al. Antineutrophil cytoplasmic autoantibodies and anti-saccharomyces cerevisiae antibodies in inflammatory bowel diseases[J]. Turk J Gastroenterol, 2004, 15(4):238-242.
17. Demirsoy H, Ozdil K, Ersoy O, et al. Anti-pancreatic antibody in Turkish patients with inflammatory bowel disease and first-degree relatives[J]. World J Gastroenterol, 2010, 16(45):5732-5738.
18. Homsak E, Micetić-Turk D, Bozic B. Autoantibodies pANCA, GAB and PAB in inflammatory bowel disease:prevalence, charac-teristics and diagnostic value[J]. Wien Klin Wochenschr, 2010, 122 Suppl 2:19-25.
19. Fagerhol MK, Dale I, Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells[J]. Bull Eur Physiopathol Respir, 1980, 16 Suppl:273-282.
20. Rugtveit J, Brandtzaeg P, Halstensen TS, et al. Increased macro-phage subset in inflammatory bowel disease:apparent recruitment from peripheral blood monocytes[J]. Gut, 1994, 35(5):669-674.
21. Røseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein[J]. Digestion, 1997, 58(2):176-180.
22. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease[J]. Dig Liver Dis, 2009, 41(1):56-66.
23. 沈姞, 李俊霞, 王化虹, 等.粪便钙卫蛋白对溃疡性结肠炎的诊断及预测复发的价值[J].肠外与肠内营养, 2011, 18(5):272-276.
24. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes[J]. Inflamm Bowel Dis, 2013, 19(2):332-341.
25. Lobatón T, Rodríguez-Moranta F, Lopez A, et al. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis[J]. Inflamm Bowel Dis, 2013, 19(5):1034-1042.
26. Mao R, Xiao YL, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases:a meta-analysis of pros-pective studies[J]. Inflamm Bowel Dis, 2012, 18(10):1894-1899.
27. 张颖, 王英德.粪便钙卫蛋白、抗中性粒细胞胞浆抗体检测在溃疡性结肠炎诊断中的价值比较[J].中华临床医师杂志:电子版, 2012, 6(6):1620-1622.
28. 王少东, 施惠, 陆恒, 等.粪便钙卫蛋白在全消化系统疾病鉴别诊断中的意义[J].胃肠病学, 2012, 17(4):237-239.
29. Vieira A, Fang CB, Rolim EG, et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin:correlation with laboratory parameters, clinical, endoscopic and histological indexes[J]. BMC Res Notes, 2009, 2:221.
30. Gisbert JP, Bermejo F, Pérez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse[J]. Inflamm Bowel Dis, 2009, 15(8):1190-1198.
31. 向军英, 欧阳钦, 李国栋.粪便乳铁蛋白在评价溃疡性结肠炎活动性中的价值[J].中华医学杂志, 2007, 87(32):2262-2264.
32. Fahlgren A, Hammarström S, Danielsson A, et al. Increased expression of antimicrobial peptides and lysozyme in colonic epithelial cells of patients with ulcerative colitis[J]. Clin Exp Immunol, 2003, 131(1):90-101.
33. Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis:a prospective multicentre comparison of predicting outcomes and monitoring response[J]. Gut, 2010, 59(9):1207-1212.
34. Johnson MW, Maestranzi S, Duffy AM, et al. Faecal M2-pyruvate kinase:a novel, noninvasive marker of ileal pouch inflammation[J]. Eur J Gastroenterol Hepatol, 2009, 21(5):544-550.
35. Chung-Faye G, Hayee B, Maestranzi S, et al. Fecal M2-pyruvate kinase (M2-PK):a novel marker of intestinal inflammation[J]. Inflamm Bowel Dis, 2007, 13(11):1374-1378.
36. Däbritz J, Langhorst J, Lügering A, et al. Improving relapse prediction in inflammatory bowel disease by neutrophil-derived S100A12[J]. Inflamm Bowel Dis, 2013, 19(6):1130-1138.
37. Kaiser T, Langhorst J, Wittkowski H, et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome[J]. Gut, 2007, 56(12):1706-1713.

Previous Article
Science and Ethics in Conducting Cardiothoracic Surgery with Da Vinci Surgical System in China: A Systematic Review
Next Article

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Significance of Laboratory Examination in The Diagnosis of Ulcerative Colitis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content